Progressive and Reversible Conduction Disease With Checkpoint Inhibitors-Reference-Cited by-同舟云学术

Progressive and Reversible Conduction Disease With Checkpoint Inhibitors

Published:2017-10 Issue:10 Volume:33 Page:1335.e13-1335.e15
ISSN:0828-282X
Container-title:Canadian Journal of Cardiology
language:en
Short-container-title:Canadian Journal of Cardiology

Author:

Reddy Neeti,Moudgil Rohit,Lopez-Mattei Juan C.,Karimzad Kaveh,Mouhayar Elie N.,Somaiah Neeta,Conley Anthony P.,Patel Shreyaskumar,Giza Dana E.,Iliescu Cezar

Publisher

Elsevier BV

Subject

Cardiology and Cardiovascular Medicine

Reference5 articles.

1. Safety profiles of anti-CTLA-4 and anti-PD-1 antibodies alone and in combination;Boutros;Nat Rev Clin Oncol,2016

2. Fulminant myocarditis with combination immune checkpoint blockade;Johnson;N Engl J Med,2016

3. Acute heart failure due to autoimmune myocarditis under pembrolizumab treatment for metastatic melanoma;Laubli;J Immunother Cancer,2015

4. PD-1 deficiency results in the development of fatal myocarditis in MRL mice;Wang;Int Immunol,2010

5. Loss of CTLA 4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4;Tivol;Immunity,1995

Cited by 49 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Cardiovascular toxicity of immune therapies for cancer;BMJ;2024-05-15

2. Immune checkpoint inhibitors break whose heart? Perspectives from cardio-immuno-oncology;Genes & Diseases;2024-03

3. Case Report: Temporary pacing using active fixation lead and invasive electrophysiology studies for immune checkpoint inhibitor associated reversible advanced atrioventricular block;Frontiers in Cardiovascular Medicine;2024-02-05

4. Immune Checkpoint Inhibitors and Their Cardiovascular Adverse Effects;Oncology Reviews;2023-11-17

5. Immune checkpoint inhibitor-related myocarditis: current understanding and potential diagnostic and therapeutic strategies;Expert Opinion on Drug Safety;2023-09-04